Journal of Hematology & Oncology is the official journal of the Chinese American Hematologist and Oncologist Network.
Articles
Page 5 of 39
-
Citation: Journal of Hematology & Oncology 2022 15:151
-
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
Extramedullary multiple myeloma (EMD) is an aggressive subentity of multiple myeloma (MM) with poor prognosis. As more innovative therapeutic approaches are needed for the treatment of MM with EMD, we conducte...
Citation: Journal of Hematology & Oncology 2022 15:150 -
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
JX-594 is an oncolytic vaccinia virus genetically modified to replicate selectively in tumor cells. Metronomic chemotherapy has shown preclinical synergy with oncolytic viruses. We report here the results of t...
Citation: Journal of Hematology & Oncology 2022 15:149 -
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) has become curable over 95% patients under a complete chemo-free treatment with all-trans retinoic acid (ATRA) and arsenic trioxide in low-risk patients. Minimizing chemother...
Citation: Journal of Hematology & Oncology 2022 15:148 -
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Continuous cell division is a hallmark of cancer, and the underlying mechanism is tumor genomics instability. Cell cycle checkpoints are critical for enabling an orderly cell cycle and maintaining genome stabi...
Citation: Journal of Hematology & Oncology 2022 15:147 -
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair
DNA lesions induced by alkylating agents are repaired by two canonical mechanisms, base excision repair dependent on poly(ADP) ribose polymerase 1 (PARP1) and the other mediated by O6-methylguanine (O6meG)-DNA m...
Citation: Journal of Hematology & Oncology 2022 15:146 -
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality
Metastatic prostate cancer (PC) is a leading cause of cancer death in men worldwide. Targeting of the culprits of disease progression is an unmet need. Interleukin (IL)-30 promotes PC onset and development, bu...
Citation: Journal of Hematology & Oncology 2022 15:145 -
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
We assessed the mechanism by which multiple myeloma (MM) shapes the bone marrow (BM) microenvironment and affects MΦ polarization.
Citation: Journal of Hematology & Oncology 2022 15:144 -
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
The United States Food and Drug Administration (US FDA) has always been a forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs (excluding vaccines, cell-based therapies, and gene t...
Citation: Journal of Hematology & Oncology 2022 15:143 -
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1/PD-L1 (α-PD-1/PD-L1) therapy. Our previous study reported the potent antitumor activity of anti-TGF-...
Citation: Journal of Hematology & Oncology 2022 15:142 -
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma
Besides featured glucose consumption, recent studies reveal that cancer cells might prefer “addicting” specific energy substrates from the tumor microenvironment (TME); however, the underlying mechanisms remai...
Citation: Journal of Hematology & Oncology 2022 15:141 -
The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy
Pediatric cancers are the driving cause of death for children and adolescents. Due to safety requirements and considerations, treatment strategies and drugs for pediatric cancers have been so far scarcely stud...
Citation: Journal of Hematology & Oncology 2022 15:140 -
Gene and cell therapies in China: booming landscape under dual-track regulation
The booming of gene and cell therapy (GCT) worldwide in recent years has been observed, especially in the field of cancers. In order to provide the comprehensive GCT landscape in China with a focus on differen...
Citation: Journal of Hematology & Oncology 2022 15:139 -
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target fo...
Citation: Journal of Hematology & Oncology 2022 15:138 -
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer
Circulating tumor DNA (ctDNA) has been proven as a marker for detecting minimal residual diseases following systemic therapies in mid-to-late-stage non-small-cell lung cancers (NSCLCs) by multiple studies. How...
Citation: Journal of Hematology & Oncology 2022 15:137 -
Evidence-based expert consensus on the management of primary central nervous system lymphoma in China
Primary central nervous system lymphoma (PCNSL) is a type of central nervous system restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell lymphoma. To provide specific, evi...
Citation: Journal of Hematology & Oncology 2022 15:136 -
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
Transforming growth factor-β (TGF-β) signaling has a paradoxical role in cancer progression, and it acts as a tumor suppressor in the early stages but a tumor promoter in the late stages of cancer. Once cancer...
Citation: Journal of Hematology & Oncology 2022 15:135 -
Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with multiple roles in tumour growth, cell invasion and metastasis. We have previously established GSK-3 as an upstream regulator of PD-1 gene ex...
Citation: Journal of Hematology & Oncology 2022 15:134 -
Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets
Regulated cell death (RCD) is a critical and active process that is controlled by specific signal transduction pathways and can be regulated by genetic signals or drug interventions. Meanwhile, RCD is closely ...
Citation: Journal of Hematology & Oncology 2022 15:133 -
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies
Poor targeting of therapeutics leading to severe adverse effects on normal tissues is considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug delivery systems have provided an ...
Citation: Journal of Hematology & Oncology 2022 15:132 -
Liquid biopsy: current technology and clinical applications
Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), a...
Citation: Journal of Hematology & Oncology 2022 15:131 -
Correction to: A novel melittin nano-liposome exerted excellent anti-hepatocellular carcinoma efficacy with better biological safety
Citation: Journal of Hematology & Oncology 2022 15:130 -
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Epithelial–mesenchymal transition (EMT) is an essential process in normal embryonic development and tissue regeneration. However, aberrant reactivation of EMT is associated with malignant properties of tumor c...
Citation: Journal of Hematology & Oncology 2022 15:129 -
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1
circRNA has been established to play a pivotal role in tumorigenesis development in a variety of cancers; nevertheless, the biological functions and molecular mechanisms of hypoxia-induced exosomal circRNAs in...
Citation: Journal of Hematology & Oncology 2022 15:128 -
ASXL1/2 mutations and myeloid malignancies
Myeloid malignancies develop through the accumulation of genetic and epigenetic alterations that dysregulate hematopoietic stem cell (HSC) self-renewal, stimulate HSC proliferation and result in differentiatio...
Citation: Journal of Hematology & Oncology 2022 15:127 -
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first co...
Citation: Journal of Hematology & Oncology 2022 15:126 -
Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients
Analysis of circulating free DNA (cfDNA) is a promising tool for personalized management of colorectal cancer (CRC) patients. Untargeted cfDNA analysis using whole-genome sequencing (WGS) does not need a prior...
Citation: Journal of Hematology & Oncology 2022 15:125 -
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and an increased risk of progression to acute ...
Citation: Journal of Hematology & Oncology 2022 15:124 -
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)
The vast majority of our knowledge regarding cancer radiobiology and the activation of radioresistance mechanisms emerged from studies using external beam radiation therapy (EBRT). Yet, less is known about the...
Citation: Journal of Hematology & Oncology 2022 15:123 -
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR
Circular RNAs (circRNAs) represent a novel type of regulatory RNA characterized by high evolutionary conservation and stability. CircRNAs are expected to be potential diagnostic biomarkers and therapeutic targ...
Citation: Journal of Hematology & Oncology 2022 15:122 -
Recent advances in therapeutic strategies for triple-negative breast cancer
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC) with a poor prognosis. Current treatment options are limited to surgery, adjuvant chemotherapy and radiotherapy; however...
Citation: Journal of Hematology & Oncology 2022 15:121 -
Posttranslational control of lipogenesis in the tumor microenvironment
Metabolic reprogramming of cancer cells within the tumor microenvironment typically occurs in response to increased nutritional, translation and proliferative demands. Altered lipid metabolism is a marker of t...
Citation: Journal of Hematology & Oncology 2022 15:120 -
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response
There is a paucity of information about molecularly driven therapy in osteosarcomas. We report a 31-year-old woman with chemotherapy–refractory metastatic osteosarcoma who was successfully treated with the com...
Citation: Journal of Hematology & Oncology 2022 15:119 -
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolu...
Citation: Journal of Hematology & Oncology 2022 15:118 -
Connecting telomere maintenance and regulation to the developmental origin and differentiation states of neuroblastoma tumor cells
A cardinal feature that distinguishes clinically high-risk neuroblastoma from low-risk tumors is telomere maintenance. Specifically, neuroblastoma tumors with either active telomerase or alternative lengthenin...
Citation: Journal of Hematology & Oncology 2022 15:117 -
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to COVID-19 related poor outcomes, including thrombosis and death, due to the advanced age, the presence of comorbidities, and the disea...
Citation: Journal of Hematology & Oncology 2022 15:116 -
Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry
Patients with follicular lymphoma (FL) who experience disease progression within 24 months (POD24) have inferior outcomes. The tumor immune microenvironment (TIME) plays a crucial role in pathogenesis and prog...
Citation: Journal of Hematology & Oncology 2022 15:115 -
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway
Lung adenocarcinoma (LUAD) is the leading cause of death worldwide. However, the roles of long noncoding RNAs (lncRNAs) hijacked by super-enhancers (SEs), vital regulatory elements of the epigenome, remain elu...
Citation: Journal of Hematology & Oncology 2022 15:114 -
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
BCR-ABL1T315I mutations confer resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Olverembatinib is a new potent BCR-ABL1 TKI with preclinical activity against T315I-mutated CML. I...
Citation: Journal of Hematology & Oncology 2022 15:113 -
RETRACTED ARTICLE: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA
Although a substantial increase in the survival of patients with other cancers has been observed in recent decades, pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest diseases. No effective s...
Citation: Journal of Hematology & Oncology 2022 15:112 -
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
The discovery of immune checkpoint inhibitors (ICIs) has now been universally acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of checkpoint molecules: anti-programmed c...
Citation: Journal of Hematology & Oncology 2022 15:111 -
Targeting macrophages in hematological malignancies: recent advances and future directions
Emerging evidence indicates that the detection and clearance of cancer cells via phagocytosis induced by innate immune checkpoints play significant roles in tumor-mediated immune escape. The most well-describe...
Citation: Journal of Hematology & Oncology 2022 15:110 -
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
Multiple Myeloma (MM) is a progressive plasma cell neoplasm characterized by heterogeneous clonal expansion. Despite promising response rates achieved with anti-BCMA CAR-T cell therapy, patients may still rela...
Citation: Journal of Hematology & Oncology 2022 15:109 -
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients
The pathophysiology of COVID-19-associated coagulopathy is complex and not fully understood. SARS-CoV-2 spike protein (SP) may activate platelets and interact with fibrin(ogen). We aimed to investigate whether...
Citation: Journal of Hematology & Oncology 2022 15:108 -
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry
Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by pathogenic TP53 variants. The condition represents one of the most relevant genetic causes of cancer in children and adults due to its freq...
Citation: Journal of Hematology & Oncology 2022 15:107 -
Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma
Multiple myeloma (MM) and its precursors monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM) are 2–3 times more common in African Americans (AA) than European Americans (EA)....
Citation: Journal of Hematology & Oncology 2022 15:106 -
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study
This study prospectively compared the efficacy and safety between matched related donor-hematopoietic stem cell transplantation (MRD-HSCT) (n = 108) and immunosuppressive therapy (IST) plus eltrombopag (EPAG) (IS...
Citation: Journal of Hematology & Oncology 2022 15:105 -
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity
Characterized by the expression of the critical transcription factor forkhead box protein P3, regulatory T (Treg) cells are an essential part of the immune system, with a dual effect on the pathogenesis of aut...
Citation: Journal of Hematology & Oncology 2022 15:104 -
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an expected overall survival (OS) of 3–5 months. Eltanexor is an inves...
Citation: Journal of Hematology & Oncology 2022 15:103 -
Correction: hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype
Citation: Journal of Hematology & Oncology 2022 15:102
-
Official journal of
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Instructions for authors
- Sign up for article alerts and news from this journal
Follow
Annual Journal Metrics
-
2022 Citation Impact
28.5 - 2-year Impact Factor
23.1 - 5-year Impact Factor
4.045 - SNIP (Source Normalized Impact per Paper)
6.046 - SJR (SCImago Journal Rank)2023 Speed
5 days submission to first editorial decision for all manuscripts (Median)
59 days submission to accept (Median)2023 Usage
3,173,795 downloads
2,671 Altmetric mentions
On the blog
-
-
Winners of the 2022 Cardio-Oncology Journal Prize
06 April 2023
-
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).